Mylan : Earnings Presentation

Forward-Looking Statements

This presentation contains "forward-looking statements." These statements are made pursuant to the safe harbor provisions of thePrivate Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, our revised 2018 financial guidance and any otherstatements about Mylan's futureoperations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations andtargets for future periods. These may often be identified by the use of words such as "will," "may," "could," "should," "would," "project," "believe," "anticipate," "expect," "plan," "estimate," "forecast," "potential," "pipeline," "intend," "continue," "target" and variations of these words or comparable words. Because forward-looking

statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; failure to

achieve expected or targeted future financial and operating performance and results; uncertainties regarding future demand, pricing and reimbursement for ourproducts; any regulatory, legal, or other impediments to Mylan's ability to bring new products to market, including, but notlimited to, where Mylan uses its business

judgment and decides to manufacture, market, and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s)have not been finally resolved by the courts (i.e., an "at-risk launch"); success of clinical trials and Mylan's ability to execute on new product opportunities; any changes

in or difficulties with our manufacturing facilities, supply chain or inventory or our ability to meet anticipated demand; the scope, timing, and outcome of any ongoing legal proceedings, including government investigations, and the impact of any such proceedings on our financial condition, results of operations, and/or cash flows; theability to meet expectations regarding the accounting and tax treatments of acquisitions, including Mylan's acquisition of MylanInc. and Abbott Laboratories' non-U.S.

developed markets specialty and branded generics business; changes in relevant tax and other laws, including but not limited to changes in the U.S. tax code and healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any significant breach of data security or data privacy or disruptions to our informationtechnology systems; the ability to protect intellectual property and preserve intellectual property rights; the effect of any changes in customer and supplier relationshipsand customer purchasing patterns; the ability to attract and retain key personnel; the impact of competition; identifying, acquiring, and integrating complementary or strategic acquisitions of other companies, products, or assets being more difficult, time-consuming or costly than anticipated; the possibility that Mylan may be unable to achieve expected synergies and operating efficiencies in connection with strategic acquisitions or restructuring programs within the expected time-frames or at all; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions and global exchange rates; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, inaccordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and related standardsor on an adjusted basis. For moredetailed information on the risks and uncertainties associated with Mylan's business activities, see the risks described in Mylan's Annual Report on Form 10-K for theyear ended December 31, 2017, as amended, and our other filings with the Securities and Exchange Commission ( the "SEC"). Youcan access Mylan's filings with the

SEC through the SEC website atwww.sec.govor through our website, and Mylan strongly encourages you to do so. Mylan routinely posts information that may be

important to investors on our website at investor.mylan.com, and we use this website address as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). The contents of our website are not incorporated into this presentation. Mylan

undertakes no obligation to update any statements herein for revisions or changes after the date of this presentation.

Q2 2018 Financial Highlights

($ in millions, except for Adjusted EPS and Percentages)	Q2 2018	Q2 2017	Change
Total Revenues	$2,808.3	$2,962.2	(5%)
Adjusted Gross Margins*	53.3%	53.8%	(50 bps)
Adjusted R&D* as % of Total Revenues	5.1%	5.8%	(70 bps)
Adjusted SG&A* as % of Total Revenues	19.8%	19.7%	10 bps
AdjustedNetEarnings*	$551.5	$589.9	(7%)
Adjusted EPS*	$1.07	$1.10	(3%)
($ in millions, except for Percentages)	Q2 2018 YTD	Q2 2017 YTD	Change
Adjusted Net Cash Provided by Operating Activities*	$1,400.9	$1,200.0	+17%
Capital Expenditures	$75.9	$109.3	(31%)
Adjusted Free Cash Flow*	$1,325.0	$1,090.7	+22%

*Adjusted metrics are non-GAAP financial measures. Please see the Appendix or investor.mylan.com for the most directly comparable U.S. GAAP financial measures and reconciliations of such non-

GAAP financial measures to those GAAP measures.

Q2 2018 Segment Performance

($ in millions)

Net Sales

Segment Profitability*

(1)

$645.0

$462.4(1)

Net Sales

• - Lower Volumes on Existing Products, Including EpiPen, Primarily Drivenby the Timing of Purchases of our Products by Customers and Restructuring and Remediation Program at the Morgantown Manufacturing Facility

• - Slightly Lower Pricing

• - Implementation of New Accounting Standards

• + New Product Sales

Adjusted Segment Profitability

Q2 2017

Q2 2018

(1)Reported Segment Profitability of $375 million, Adjusted for ~$87Mof Morgantown Restructuring and Remediation Program Expenses

$252.7

$238.1

• + Favorable FX Impacts on Net Sales

• + New Product Sales

• −Lower Volumes and Pricing

Q2 2017

Q2 2018

*Segment Profitability represents segment gross profit less direct R&D expenses and direct SG&A expenses. See Mylan's Form 10-K for the year ended December 31, 2017 for more information.

$138.5

$174.0

• + New Product Sales Primarily in ARV Franchise

• + +22% Growth in Emerging Markets

• - Lower Pricing

Q2 2017

Q2 2018

Revised 2018 Financial Guidance

($ in millions, except for Adjusted EPS)

Total Revenues

Adjusted EPS*

Adjusted Free Cash Flow*

Previous$11,750-$13,250

$5.20-$5.60

$2,100-$2,500

* Adjusted metrics are non-GAAP financial measures. Please see the Appendix. ** Calculation based on mid-point of revised guidance.

Adjusted Free Cash Flow*$2.3B**Segment Revenue Guidance % vs 2017

North AmericaMid-teen Decline

Europe & ROW Remain On-Track to Initial Guidance

High-single Digits Growth

Total RevenuesFLAT** vs 2017

Adjusted EPS*+4%** vs 2017